
In a network meta-analysis of 24 studies involving 6208 patients with Idiopathic Pulmonary Fibrosis (IPF), researchers assessed the safety and efficacy of 13 drugs. Results indicated no significant difference in Serious Adverse Events (SAEs) between the drugs and placebo. However, Warfarin showed higher all-cause mortality. Nintedanib and Pirfenidone demonstrated better efficacy in slowing lung function decline, with higher safety. Conversely, Warfarin and Ambrisentan exhibited poorer safety and efficacy, discouraging their use for IPF. Pamrevlumab may emerge as a crucial future treatment. Overall, Nintedanib and Pirfenidone are recommended for clinical use in IPF.
Like
Save
Share